Non-Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral diseases Pub Date : 2025-03-03 DOI:10.1111/odi.15288

S A Hamza, R Paolini, N M O'Brien-Simpson, W Singleton, R Patini, M McCullough, A Celentano

{"title":"Non-Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer.","authors":"S A Hamza, R Paolini, N M O'Brien-Simpson, W Singleton, R Patini, M McCullough, A Celentano","doi":"10.1111/odi.15288","DOIUrl":null,"url":null,"abstract":"Background: Oral squamous cell carcinoma (OSCC) represents a significant global oral health concern. Non-anticoagulant heparin (NH) emerges as a promising solution considering the enhanced survival observed with anticoagulants in cancer treatment.Methods: We used the MTS assay (0/24/48/72 h), scratch assay (MuviCyte, 0-18 h), invasion Matrigel (24 h), and cytotoxic assay (0-24 h) to assess the in vitro effects of NH and heparin (10, 20, 40, 80 U/mL) on three oral human cell lines (H400/H357/OKF6) as well as their ability to interfere with the chemotherapeutic agents 5FU and cisplatin (1-5 μg/mL).Results: Remarkably, NH not only significantly induced a significant cytotoxic effect on both cancer cell lines at 80 U/mL but also inhibited proliferation at 48/72 h to a comparable extent as heparin. Notably, neither drug exhibited cytotoxic effects on the normal cells. Furthermore, in H400/H357 cells, both heparin and NH significantly inhibit the cell migration and invasion rate. Importantly, the combination of these drugs with commonly used chemotherapeutic agents for OSCC treatment did not compromise their efficacy against the tested cell lines.Conclusion: NH demonstrates promising potential without compromising the efficacy of commonly used chemotherapeutic agents. These results underscore the need for the translation of this research to preclinical animal models.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.15288","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Oral squamous cell carcinoma (OSCC) represents a significant global oral health concern. Non-anticoagulant heparin (NH) emerges as a promising solution considering the enhanced survival observed with anticoagulants in cancer treatment.

Methods: We used the MTS assay (0/24/48/72 h), scratch assay (MuviCyte, 0-18 h), invasion Matrigel (24 h), and cytotoxic assay (0-24 h) to assess the in vitro effects of NH and heparin (10, 20, 40, 80 U/mL) on three oral human cell lines (H400/H357/OKF6) as well as their ability to interfere with the chemotherapeutic agents 5FU and cisplatin (1-5 μg/mL).

Results: Remarkably, NH not only significantly induced a significant cytotoxic effect on both cancer cell lines at 80 U/mL but also inhibited proliferation at 48/72 h to a comparable extent as heparin. Notably, neither drug exhibited cytotoxic effects on the normal cells. Furthermore, in H400/H357 cells, both heparin and NH significantly inhibit the cell migration and invasion rate. Importantly, the combination of these drugs with commonly used chemotherapeutic agents for OSCC treatment did not compromise their efficacy against the tested cell lines.

Conclusion: NH demonstrates promising potential without compromising the efficacy of commonly used chemotherapeutic agents. These results underscore the need for the translation of this research to preclinical animal models.

查看原文本刊更多论文

非抗凝肝素：一种口腔癌新治疗方法的体外研究。

背景：口腔鳞状细胞癌（OSCC）是一个重要的全球口腔健康问题。考虑到抗凝治疗在癌症治疗中观察到的提高生存率，非抗凝肝素（NH）成为一种有希望的解决方案。方法：采用MTS法（0/24/48/72 h）、刮擦法（MuviCyte, 0-18 h）、侵袭Matrigel法（24 h）和细胞毒法（0-24 h）评价NH和肝素（10、20、40、80 U/mL）对3种口服人细胞株（H400/H357/OKF6）的体外作用，以及对化疗药物5FU和顺铂（1-5 μg/mL）的干扰能力。结果：值得注意的是，NH在80 U/mL浓度下不仅对两种癌细胞都有明显的细胞毒作用，而且在48/72 h时对增殖的抑制程度与肝素相当。值得注意的是，两种药物都没有对正常细胞产生细胞毒性作用。此外，在H400/H357细胞中，肝素和NH均能显著抑制细胞迁移和侵袭率。重要的是，这些药物与常用的化疗药物联合用于OSCC治疗，并没有损害它们对被测细胞系的疗效。结论：NH在不影响常用化疗药物疗效的情况下具有良好的应用前景。这些结果强调了将这项研究转化为临床前动物模型的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.